Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
← catalyst calendarNCT07444567 · readout in 1,233 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
230estimated
Sites
45
Countries
Argentina, Austria, Belgium +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-24 | actual | When the study began enrolling |
| Primary completion | 2030-01-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-03 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Asthma
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Hypereosinophilic Syndrome (HES)
Intervention
- Drug: Benralizumab — also filed as Fasenra
Primary outcome
what the primary-completion date above is the date OFSafety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab
measured From baseline until 8 weeks after the last dose of benralizumab
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed